Moderna Recursion: Which Cutting-Edge Path Is Best in 2026
Two biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...
Starting financial planning for retirement is crucial for a secure future. Learn the best time to begin and set your goals effectively.
20,958 articlesTwo biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...
Paradigm just closed a $1.2B fund, signaling a bold move at the intersection of crypto and AI. This Morning Minute ex...
New labor data reveals a troubling disconnect: participation falls while unemployment headlines stay resilient. Inves...
Artificial intelligence is reshaping capital flows across tech and beyond. This guide identifies three core AI infras...
A fresh $75 million fund backs consumer brands with cultural punch. The 29-year investor went from early, risky bets ...
River Road Asset Management just added a notable new position in AptarGroup, acquiring 917,670 shares valued at about...
As electric-vehicle charging scales up, ChargePoint's 2026 earnings outlook becomes a key signal for investors. This ...
A quarterly filing may seem dry, but it can reveal game-changing shifts in ultra-wealthy portfolios. This article exp...
The S&P 500 dropped around 1.5% as crude surged on geopolitical worries, reviving inflation fears and tempering expec...
With policy tailwinds and growing demand, the solar sector remains a core focus for 2026. Here are the best solar sto...
A deep-dive look at electroCore's 2026 earnings narrative. This article unpacks Q1 signals, growth drivers, and pract...
A big fund move can shift sentiment and pricing. This article breaks down the implications of baillie gifford dumps 2...